Cost-Effectiveness of Brentuximab Vedotin in Relapsed or Refractory Hodgkin's Lymphoma Following Autologous Stem Cell Transplant in Taiwan
Nov 1, 2016, 00:00
10.1016/j.jval.2016.08.269
https://www.valueinhealthjournal.com/article/S1098-3015(16)30849-X/fulltext
Title :
Cost-Effectiveness of Brentuximab Vedotin in Relapsed or Refractory Hodgkin's Lymphoma Following Autologous Stem Cell Transplant in Taiwan
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)30849-X&doi=10.1016/j.jval.2016.08.269
First page :
A888
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
2731